STOCK TITAN

Stoke Therapeutics, Inc. - STOK STOCK NEWS

Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.

Stoke Therapeutics, Inc. (NASDAQ: STOK) is a pioneering biotechnology company dedicated to addressing the root causes of severe genetic diseases. With a focus on developing antisense oligonucleotide (ASO) medicines, Stoke aims to increase gene expression by targeting RNA splicing. This innovative approach is designed to upregulate protein production, offering potential treatments for conditions that currently have limited therapeutic options.

One of the key technologies driving Stoke's mission is its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This advanced method allows for precise modulation of RNA to restore protein levels, providing a novel way to treat genetic disorders. The company's lead candidate, STK-001, is currently in clinical trials for the treatment of Dravet syndrome, a severe form of genetic epilepsy characterized by frequent and prolonged seizures. This promising candidate exemplifies Stoke's commitment to transforming the lives of patients with debilitating conditions.

Beyond Dravet syndrome, Stoke Therapeutics is actively exploring the application of its ASO platform to other severe genetic diseases. The company’s robust pipeline and strategic partnerships underscore its potential to deliver innovative therapies that address significant unmet medical needs.

Financially, Stoke Therapeutics has maintained a strong position, attracting strategic investments and partnering with leading research institutions to advance its clinical programs. The company primarily operates within the United States, leveraging its expertise and innovative technology to push the boundaries of genetic medicine.

For investors and stakeholders, Stoke Therapeutics represents a unique opportunity within the biotechnology sector, with its cutting-edge approach to genetic disease treatment and a clear focus on clinical and commercial milestones. Stay tuned for the latest updates and developments from Stoke Therapeutics as it continues to make significant strides in the field of genetic medicine.

Rhea-AI Summary
Stoke Therapeutics, Inc. reported financial results for the full year ended December 31, 2023, with $201.4 million in cash, cash equivalents, and marketable securities expected to fund operations until 2025. Revenue for 2023 was $8.8 million, net loss was $104.7 million, research and development expenses were $82.2 million, and general and administrative expenses were $41.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.31%
Tags
-
Rhea-AI Summary
Stoke Therapeutics (STOK) announces positive data from Phase 1/2a studies of STK-001 for Dravet syndrome treatment, showing substantial reductions in convulsive seizure frequency and cognitive improvements. The company plans to discuss registrational study design with regulatory agencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.31%
Tags
none
-
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) has granted stock options to 2 new employees, totaling 13,300 shares of common stock, with an exercise price of $4.99 per share. Each option will vest over a 4-year period, with 1/4th of the shares vesting on the one-year anniversary and the remaining shares vesting monthly over the following 36 months, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Rhea-AI Summary
Stoke Therapeutics, Inc. (STOK) announces strategic priorities and anticipated milestones for 2024, including data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome, end of Phase 1/2a study results, OLE data from patients receiving ongoing treatment, and pending Phase 3 planning meetings with regulators. As of September 30, 2023, the company had $214.7 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company focuses on upregulating protein expression with RNA-based medicines to address severe diseases. A live audio webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) presented clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting, highlighting STK-001's potential to address Dravet syndrome. The 2-year natural history study showed no meaningful improvement in convulsive seizures despite treatment with anti-seizure medicines. However, STK-001 clinical studies demonstrated substantial and sustained reductions in seizure frequency and improvements in cognition and behavior, supporting the potential for disease modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
none
Rhea-AI Summary
Stoke Therapeutics (STOK) presents new data on STK-001 at the American Epilepsy Society 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
conferences
-
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) reported positive data from ongoing studies of STK-001, showing substantial reductions in seizure frequency and improvements in cognition and behavior in patients with Dravet syndrome. The company plans to complete Phase 1/2a studies by year-end and meet with regulators to discuss a Phase 3 study design in 1H 2024. As of September 30, 2023, Stoke had $214.7 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.53%
Tags
-
Rhea-AI Summary
Stoke Therapeutics grants stock option to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
none
Rhea-AI Summary
Stoke Therapeutics to participate in panel presentation at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
conferences

FAQ

What is the current stock price of Stoke Therapeutics (STOK)?

The current stock price of Stoke Therapeutics (STOK) is $11.68 as of December 20, 2024.

What is the market cap of Stoke Therapeutics (STOK)?

The market cap of Stoke Therapeutics (STOK) is approximately 594.8M.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics develops antisense oligonucleotide medicines to increase gene expression for treating severe genetic diseases.

What is the TANGO platform?

TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke's proprietary technology for modulating RNA to restore protein levels.

What is STK-001?

STK-001 is Stoke's lead compound, currently in clinical testing for the treatment of Dravet syndrome, a severe genetic epilepsy.

Where does Stoke Therapeutics primarily operate?

Stoke Therapeutics primarily operates in the United States.

What is Dravet syndrome?

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent and prolonged seizures.

How does Stoke Therapeutics' ASO technology work?

Their ASO technology targets RNA splicing to selectively upregulate protein expression, addressing the underlying cause of genetic diseases.

What other diseases is Stoke Therapeutics targeting?

Stoke is exploring the application of its ASO platform to other severe genetic diseases with significant unmet medical needs.

How is Stoke Therapeutics funded?

Stoke has attracted strategic investments and partnerships with leading research institutions to advance its clinical programs.

Why is gene expression important in treating genetic diseases?

Increasing gene expression can restore normal protein levels, potentially correcting the underlying dysfunction in genetic diseases.

What makes Stoke Therapeutics unique in the biotech sector?

Stoke's innovative TANGO platform and focus on RNA-based treatments for severe genetic diseases set it apart as a leader in genetic medicine.

Stoke Therapeutics, Inc.

Nasdaq:STOK

STOK Rankings

STOK Stock Data

594.82M
50.49M
4.77%
110.94%
12.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDFORD